【文献战报】2025年1-3月 Bioss "错过"的Top文献引用精选-商家动态-资讯-生物在线

【文献战报】2025年1-3月 Bioss "错过"的Top文献引用精选

作者:北京博奥森生物技术有限公司 暂无发布时间 (访问量:2176)

截止目前,引用Bioss产品发表的文献共35263篇,总影响因子175,814.81分,发表在Nature, Science, Cell以及Immunity等顶级期刊的文献共126篇,合作单位覆盖了清华、北大、复旦、华盛顿大学、麻省理工学院、东京大学以及纽约大学等上百所国际知名研究机构。
我们每月收集引用Bioss产品发表的文献。若您在当月已发表SCI文章,但未被我公司收集,请致电Bioss,我们将赠予现金鼓励,金额标准请参考“发文章 领奖金”活动页面。

本文主要分享引用Bioss产品发表文章至Signal Transduction and Targeted Therapy, Journal of Thoracic Oncology, Bioactive Materials, Advanced Functional Materials等期刊的10篇IF≥19的文献摘要,让我们一起欣赏吧。

 

Signal Transduction and 

Targeted Therapy [IF=52.7]

文献引用产品:

bsm-60738R | Ki67 Recombinant Rabbit mAb | IHC

bs-0646R | CD34 Rabbit pAb | IHC

作者单位:南方医科大学

摘要:Nanoparticle-based drug delivery system remains a significant challenge in the current treatment of solid tumors, primarily due to their limited penetration capabilities. Herein, we successfully engineer photodynamic gel-bombs (DCM@OPR) capable of penetrating deeply into tumor tissues utilizing the photodynamic-triggered explosive energy and receptor-mediated transcytosis, significantly enhancing the therapeutic efficacy of breast cancer. The photodynamic gel-bombs were fabricated by loading powerful components of chlorin e6 and MnO2 nanoparticles, as well as Doxorubicin, into a crosslinked Ca2+-gel. Upon exposure to laser irradiation, the obtained photodynamic gel-bombs are capable of generating explosive energy, resulting in their fragmentation into numerous nanofragments. The photodynamic-triggered explosive energy subsequently drives these nanofragments to deeply penetrate into tumor tissues through gap leakage among tumor cells. In addition, the photodynamic-triggered explosive energy also promotes the escape of those therapeutic components (including chlorin e6, MnO2 nanoparticles, and doxorubicin) and nanofragments from lysosomes. In the subsequent stages, these nanofragments also exhibit excellent transcytosis capacity, facilitating deep penetration into tumor tissues. As expected, the enhanced penetration and accumulation of therapeutic components into tumor tissues can be achieved, significantly enhancing the anti-proliferation capacity against breast cancer.

 

Journal of Thoracic 

Oncology [IF=20.8]

文献引用产品:

bs-1351R | Granzyme B Rabbit pAb | mIF

bs-20765R | CCL5/RANTES Rabbit pAb | mIF

作者单位同济大学医学院

摘要:Introduction:Accumulation of regulatory T (Treg) cells, an immunosuppressive population, limits the efficacy of immunotherapy in NSCLC. C-C motif chemokine receptor 8 (CCR8) is selectively expressed in tumor-infiltrating Treg cells and is, therefore, considered an ideal target.

Methods:The efficacy and safety of anti-CCR8 monotherapy and its combination with programmed cell death protein-1 (PD1) inhibitor were evaluated in four NSCLC-bearing mice models. To track the dynamic changes in tumor microenvironment, we performed the single-cell RNA sequencing, the single-cell T-cell receptor sequencing analysis, the flow cytometry, the multi-color immunofluorescence, and the Luminex assay on tumors after three, seven, 14, and 21 days of different treatment regimens. Then, in vitro and in vivo experiments were applied to validate our findings and explore molecular mechanisms of the synergistic effects.

Results:Across four NSCLC-bearing mice models, the combination of CCR8 antibody and PD1 inhibitor significantly reduced tumor growth (p < 0.05) without obvious mouse body weight drops and systemic cytokine storm. The anti-CCR8 therapy synergizes with PD1 blockade by remodeling the tumor microenvironment and disrupting CCR8+Treg–C-C motif chemokine ligand 5 (CCL5)+ dendritic cells (DC) interaction. Mechanistically, therapeutic depletion of CCR8+Treg cells combined with PD1 inhibitor extremely increased interleukin-12 secretion by the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway activation on CCL5+ DCs, thereby promoting cytotoxic activity of CD8+ T cells. The therapeutic potential of the CCR8 antibody LM-108 in combination with immunotherapy was observed in clinical patients with advanced NSCLC.

Conclusion:Overall, CCR8 expression on tumor-infiltrating Treg cells is correlated with immunosuppressive function on DCs and CD8+ T cells, thus impeding antitumor immunity.

 

Bioactive Materials [IF=20.3]

文献引用产品:

D-9110 | DiD perchlorate | Other

作者单位中山大学附属第三医院

摘要:Acute liver failure (ALF) is a highly lethal condition characterized by massive tissue necrosis, excessive oxidative stress, and serious inflammatory storms, necessitating prompt medical intervention. Although hepatocyte-like cells (HLCs) derived from mesenchymal stromal/stem cells (MSCs) offer a promising alternative cell source for hepatocyte therapy, their low in-vivo integration and differentiation efficiency may compromise the eventual therapeutic efficacy. To this end, MSCs are bioengineered into multicellular spheroids in the present study. The proteomic analyses and experimental results reveal that extracellular vesicles (EVs) derived from these MSC spheroids (SpEV) contain abundant highly expressed bioactive proteins and can be efficiently endocytosed by recipient cells, resulting in enhanced pro-angiogenic and antioxidative effects. In addition, MSC spheroids exhibit superior hepatic cell differentiation compared to an equivalent number of dissociated single MSCs, particularly when being co-cultured with hexagonally patterned endothelial cells in a liver lobule-like arrangement. Following orthotopic implantation in the mouse model, the enhanced paracrine effects of SpEV, combined with an immunoregulatory decellularized extracellular matrix hydrogel carrier and functional artificial liver lobules (ALL), synergically contribute to the effective amelioration of ALF, highlighting the substantial potential for clinical translation.

 

Advanced Functional 

Materials [IF=19]

文献引用产品:

bs-0296G-HRP | Goat Anti-Mouse IgG H&L, HRP conjugated | WB
作者单位:贵州医科大学附属医院

摘要:Transarterial chemoembolization (TACE) is considered the main treatment for intermediate and advanced liver cancer. Nevertheless, TACE may aggravate liver fibrosis in these patients, which could affect the therapeutic effect after TACE. Pirfenidone (PFD) exhibits significant antifibrotic effects in the liver, primarily via inhibition of hepatic stellate cells (HSCs) activation. However, owing to the high dose required for effective treatment, oral administration of PFD is associated with several side effects. This study introduces an oral folic acid (FA)-modified protein-polysaccharide PFD nanoemulsion designed to treat post-TACE liver fibrosis via liver targeting. This novel PFD oral nanoemulsion withstands gastrointestinal digestion and ensures the gastrointestinal stability of PFD. Furthermore, this nanoemulsion improves the intestinal permeability and antifibrotic efficacy of PFD at a lower dose via folate receptors expressed on both intestinal epithelial cells and activated HSCs. In conclusion, this FA-modified protein-polysaccharide nanoemulsion presents a promising approach for oral PFD delivery to effectively ameliorate fibrosis after TACE for liver cancer.

 

Advanced Functional 

Materials [IF=19]

文献引用产品:

bs-40295G-HRP | AffiniPure Goat Anti-Rabbit IgG H&L, HRP conjugated | IHC
作者单位:重庆医科大学
摘要:The extensive intercellular material and information flow in the immune microenvironment is instructive to the development of targeted delivery strategies, but has received little attention previously. In this study, efferocytosis, an important link of material and information flow during inflammation, is creatively used to achieve a significant increase of targeted delivery efficiency. A tailored “neutrophil airfreighter” strategy is developed to deliver plenty of siRNA-loaded nanocomplexes (FCM@siNPs) to mtDNA-releasing sentinel mononuclear phagocytes (MPs) in vivo, providing them with immuno-directed information. FCM@siNPs consist of siRNA-loaded mesoporous silicon modified with engineered NIH3T3 cell membranes. Based on this innovative strategy, the delivery efficiency of FCM@siNPs to MPs is improved by 360% in vitro and 120% in vivo. FCM@siNPs could effectively inhibit periodontal inflammation in mice by precisely regulating the mtDNA-induced inflammatory response in MPs. This study suggests the potential of the organismal material and information flow in the design of efficient targeted delivery strategies.

Advanced Functional 

Materials [IF=19]

文献引用产品:

bs-1313R |  VEGFA Rabbit pAb | IHC
bs-1134R | RUNX2 Rabbit pAb | IHC
作者单位:兰州大学
摘要:Chronic periodontitis in individuals with diabetes can exacerbate the destruction of local periodontal soft tissues and accelerate the resorption of hard tissue. Currently, effective strategies to simultaneously restore both soft and hard periodontal tissues remain insufficient. To address this challenge, a multifunctional dual-layer microneedles (d-MNs) design is proposed to regenerate both periodontal soft and hard tissues in diabetic patients. The d-MNs substrate is composed of gelatin methacryloyl (GelMA) infused with nano-hydroxyapatite (nHA), which facilitates the differentiation of osteogenic cells into osteoblasts, thereby promoting alveolar bone regeneration. The tips of the d-MNs, on the other hand, are primarily made of hyaluronic acid (HA) combined with a magnesium-based metal-organic framework (Mg-MOF) loaded with glucose oxidase (GOX). This composition creates a hypoglycemic, angiogenic, and anti-inflammatory microenvironment, which supports soft tissue repair. When implanted at the site of periodontitis, the synergistic interaction between the d-MNs substrate and tips effectively promotes the regeneration of both soft and hard tissues, as demonstrated in diabetic rat models of periodontitis. These innovative d-MNs have the potential to revolutionize traditional approaches to treating diabetic periodontitis and can see broad application in dental clinics.

 

Advanced Functional 

Materials [IF=19]

文献引用产品:

bs-2696R | S100-A8 / MRP8 Rabbit pAb | IF

作者单位:四川大学

摘要:Inhalation offers a non-invasive method to administer drugs to lungs, but achieving selective delivery to pulmonary lesions while sparing normal lung tissues remains challenging. Here, the development of an inhalable chemotactic liposome designed for targeted modulation of pulmonary pre-metastatic niche (PMN) is reported. The inhaled liposome can migrate along chemokine gradients, preferentially accumulating in chemokine-secreting PMNs within the lung. Upon localized drug release, the liposome mitigates fibrosis, and disrupts PMN evolution, thereby attenuating the pro-metastatic role of PMN as a hospitable “soil” for residual tumor cell “seeding” post-surgery. This approach further complements a sprayable hydrogel developed for immediate post-surgical application within the tumor resection cavity. While this hydrogel alone reduces the metastatic potential of postoperative tumor residues, it proves insufficient in halting the spread to lungs. However, the integration of the inhalable liposome and sprayable hydrogel into a dual-pronged strategy presents a patient-friendly method that simultaneously targets both the pro-metastatic PMN “soil” and metastatic tumor “seeds”, resulting in significant inhibition of postoperative lung metastasis.

 

Advanced Functional 

Materials [IF=19]

文献引用产品:

bs-0737R | HIF-1 Alpha Rabbit pAb | IF
bs-14305R | DHODH Rabbit pAb | IF, WB
C7074 | Fetal Bovine Serum (FBS) | Other

作者单位:广西医科大学附属肿瘤医院

摘要:Ferroptosis is a newly identified type of regulated cell death characterized by iron-dependent lipid peroxidation. Among the main ferroptosis-suppressing systems, the dihydroorotate dehydrogenase (DHODH)- ubiquinone axis is closely related to mitochondria and energy metabolism, implying that the axis protects cells from oxidative stress damage via the maintenance of redox homeostasis. However, ferroptosis initiation requires a suitable oxidative environment and a breakthrough in redox homeostatic limitations by ferroptosis-suppressing systems. Hence, the nanoparticles are rationally engineered to achieve efficient ferroptosis induction by releasing dual-release free iron and disrupting ferroptosis-suppressing systems. Atovaquone (ATO)-loaded hollow mesoporous etching zeolitic imidazolate framework-67 double-coated iron oxide/calcium phosphate (Fe3O4/CaP) is conjugated with polyethylene glycol. The external double-coated Fe3O4/CaP structure enhances the efficiency of multiple reactive oxygen species (ROS) generation promoting oxidative stress. Still, it achieves free iron dual-release to increase the content of unstable iron pools for igniting the ROS storm and lipid peroxidation spark. The release of ATO not only affects the energy metabolism of the mitochondrial respiratory chain by binding to complex III but also downregulates DHODH to restrict the ubiquinol system to disrupt the ferroptosis-suppressing systems. Therefore, the design of this composite nanomedicine provides an approach for inducing ferroptosis and a theoretical basis for clinical ferroptosis anti-tumor trials.

 

Advanced Functional

Materials [IF=19]

文献引用产品:

bsm-55544M | MMP9 Recombinant Mouse mAb | LFIA
bs-41146P | Recombinant human MMP9 protein, His | LFIA
bs-0295P | Rabbit IgG | LFIA
bs-47247P | Recombinant human MMP2 Protein, C-His (HEK293) | LFIA
D10374s | Lysozyme solution (10mg/ml) | Other

作者单位:温州医科大学

摘要:Surface-enhanced Raman scattering (SERS) substrates based on 2D semimetallic materials have emerged as novel detecting platforms for detecting at the single-molecule level due to the high charge transfer efficiency between the layered materials and analytes. However, current methods such as chemical vapor deposition (CVD) or liquid-phase exfoliation face significant challenges in simultaneously achieving high yield and low defect density in preparing layered materials, which often leads to compromises in SERS efficiency or sensitivity, thereby limiting large-scale applications. Herein, an improved electrochemical cathodic exfoliation (ECE) protocol, developed through recent advancements, is employed to produce highly uniform and solution-processable TiSe2, NbSe2, and TaSe2 monolayers with over 95% yield in 120 min. The SERS sensitivity (10−16 M for Rhodamine 6G) of 2D materials from ECE rivals that of CVD-prepared monolayers due to their low defect density. Using NbSe2 as the SERS substrate, matrix metalloproteinase-9 in tear fluid is detected across 0.01 to 100 ng mL−1, outperforming conventional enzyme-linked immunosorbent assay methods that typically detect at 1 ng mL−1. The scalability of the modified ECE process not only facilitates its integration into lateral flow immunoassays but also paves the way for bridging the gap between practical applications and highly sensitive SERS detection using 2D materials.

 

Advanced Functional

 Materials [IF=19]

文献引用产品:

bsm-60761R | CD206 Recombinant Rabbit mAb | WB, IF

bsm-33033M | GAPDH Mouse mAb, Loading Control | WB

作者单位河南省中医院附属骨科医院

摘要:Insufficient oxygen supply and elevated levels of reactive oxygen species (ROS) in rheumatoid arthritis (RA) joints synergistically exacerbate inflammation and accelerate disease progression. In this study, a hybrid nanoassembly composed of superoxide dismutase (SOD) and catalase (CAT) conjugated within a single poly(ε-caprolactone) (PCL) nanoparticle is developed for RA therapy. The synthesized nanoassembly (PSC) drives a proximity-dependent cascade reaction that efficiently scavenges ROS and generates oxygen, thereby modulating the phenotype of inflammatory macrophages in RA synovium, significantly inhibiting the secretion of pro-inflammatory cytokines, and consequently alleviating inflammation. Furthermore, PSC functions as a versatile drug delivery platform for hydrophobic small-molecule drugs. Iguratimod (IGU), an anti-rheumatic drug with bone-protective properties, is incorporated into the PSC (PSC@IGU), which is then loaded into dissolvable microneedles (MNs) to enhance drug delivery efficiency. Finally, PSC@IGU MNs demonstrate significant therapeutic effects in RA mouse models by effectively improving joint hypoxia, alleviating synovial inflammation, and preventing bone erosion. This study highlights the potential of PSC@IGU-loaded MNs for the treatment of RA, indicating their promising ability to bridge basic research with clinical translation.

北京博奥森生物技术有限公司 商家主页

地 址: 北京市通州区马驹桥镇联东U谷西区四期67号楼

联系人: 秦

电 话: 4009019800

传 真: 010-58129612

Email:sales@bioss.com.cn

相关咨询
ADVERTISEMENT